JP2016135366A - 乾燥粉末吸入器のマウスピースボタン - Google Patents
乾燥粉末吸入器のマウスピースボタン Download PDFInfo
- Publication number
- JP2016135366A JP2016135366A JP2016089266A JP2016089266A JP2016135366A JP 2016135366 A JP2016135366 A JP 2016135366A JP 2016089266 A JP2016089266 A JP 2016089266A JP 2016089266 A JP2016089266 A JP 2016089266A JP 2016135366 A JP2016135366 A JP 2016135366A
- Authority
- JP
- Japan
- Prior art keywords
- inhaler
- dry powder
- blister
- mouthpiece
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940112141 dry powder inhaler Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 92
- 239000000843 powder Substances 0.000 claims abstract description 84
- 230000007246 mechanism Effects 0.000 claims abstract description 41
- 229940079593 drug Drugs 0.000 claims description 64
- 210000003323 beak Anatomy 0.000 claims description 29
- 238000004804 winding Methods 0.000 claims description 19
- 239000013543 active substance Substances 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 230000001360 synchronised effect Effects 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 239000004811 fluoropolymer Substances 0.000 claims description 4
- 229920002313 fluoropolymer Polymers 0.000 claims description 4
- 239000011888 foil Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 3
- 229960000265 cromoglicic acid Drugs 0.000 claims description 3
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 3
- 239000002861 polymer material Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000009097 single-agent therapy Methods 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 229910021536 Zeolite Inorganic materials 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 229940095564 anhydrous calcium sulfate Drugs 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 230000002924 anti-infective effect Effects 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- 229910001570 bauxite Inorganic materials 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 239000002274 desiccant Substances 0.000 claims description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000010457 zeolite Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 8
- 208000006673 asthma Diseases 0.000 abstract description 6
- 208000023504 respiratory system disease Diseases 0.000 abstract description 6
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 2
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 2
- 230000000087 stabilizing effect Effects 0.000 description 20
- 230000004044 response Effects 0.000 description 15
- -1 polyoxymethylene Polymers 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 238000004891 communication Methods 0.000 description 5
- 229920006324 polyoxymethylene Polymers 0.000 description 5
- 238000002664 inhalation therapy Methods 0.000 description 4
- 210000000282 nail Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- 208000033116 Asbestos intoxication Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 206010003441 asbestosis Diseases 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
- BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 description 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010051235 Madarosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 description 1
- SRJDFSRXQHFSBO-UHFFFAOYSA-N acetic acid;methylcyclopropane Chemical compound CC1CC1.CC(O)=O SRJDFSRXQHFSBO-UHFFFAOYSA-N 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000028462 aluminosis Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229950010713 carmoterol Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229950003420 efletirizine Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960001508 levocetirizine Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000004021 metal welding Methods 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 229940095050 propylene Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229920000638 styrene acrylonitrile Polymers 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0023—Mouthpieces therefor retractable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
- A61M15/0026—Hinged caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0053—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal
- A61M15/0055—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal the used dosages being coiled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
- A61M15/0075—Mechanical counters having a display or indicator on a disc
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
- A61M2205/584—Means for facilitating use, e.g. by people with impaired vision by visual feedback having a color code
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
【解決手段】本発明は、呼吸器疾患、特に喘息、慢性閉塞性肺疾患(COPD)及びアレルギー性鼻炎の経口ルートによる治療に使用される乾燥粉末形態の薬剤を送達するために適切であり、デバイスの不注意な作動に由来する問題を防止する機構を有する吸入器に関する。
【選択図】 図6a
Description
−それぞれが乾燥粉末形態の薬剤を有し、等間隔に離間された複数のブリスターポケットで構成されたブリスター包装体と、
−ブリスター包装体の剥離を提供するビークと、
−患者が開封したブリスターから乾燥粉末形態の薬剤を吸入するのを可能にするマウスピースと、
−マウスピースを覆う回転式マウスピースカバーと、
−ブリスター包装体を割り出すことと、乾燥粉末形態の薬剤の吸入の準備を整えることを可能にする歯車機構と、
−上部ハウジング部材と下部ハウジング部材の間に位置し、ブリスター包装体及び歯車機構を封入するハウジングとを備え、
デバイスが作動すると割り出されるブリスター包装体の蓋シートと接触しているビークの鋭利な先端の半径が、0.05mm〜1mmの範囲にあることを特徴とする。
Claims (27)
- それぞれが乾燥粉末形態の薬剤を有し、等間隔に離間された複数のブリスターポケット(15a)で構成されたブリスター包装体(15)から乾燥粉末形態の薬剤を送達するのに適した吸入器であって、
−ブリスター包装体(15)の剥離を提供するビーク(16)と、
−患者が、開封されたブリスターから前記乾燥粉末形態の薬剤を吸入するのを可能にするマウスピース(14)と、
−マウスピース(14)を覆う回転式マウスピースカバー(2)と、
−ブリスター包装体(15)を割り出して、前記乾燥粉末形態の薬剤の吸入の準備を整えることを可能にする歯車機構と、
−上部ハウジング部材(4a)と下部ハウジング部材(4b)の間に位置し、前記ブリスター包装体及び前記歯車機構を封入するハウジング(10)と、
を備え、
前記デバイスが作動すると割り出されるブリスター包装体(15)の蓋シート(15b)と接触しているビーク(16)の鋭利な先端(16a)の半径は、0.05mm〜1mmの範囲にあることを特徴とする、吸入器。 - 前記ブリスターパックの蓋シート(15b)に接触しているビーク(16)の鋭利な先端(16a)の半径は、好ましくは、0.05mm〜0.4mmの範囲である、請求項1に記載の吸入器(1)。
- 前記マニホールドの鋭利な先端(20c)と前記ビークの鋭利な先端(16a)との間の距離は、少なくとも0.005mmである、請求項1又は2に記載の吸入器(1)。
- 前記マニホールドの鋭利な先端(20c)と前記ビークの鋭利な先端(16a)との間の距離は、好ましくは、0.005mm〜0.5mmの範囲である、請求項1又は2に記載の吸入器(1)。
- ビーク(16)及びマニホールド(20)は、好ましくは、前記吸入器のハウジング(10)内に収容される、請求項1に記載の吸入器(1)。
- 吸入デバイス(1)は、乾燥粉末形態の薬剤を送達するのに適した把持し易い手動デバイスである、請求項1〜5のいずれか1項に記載の吸入器(1)。
- 前記上部及び下部ハウジング部材上の突起(23a,23b;24a,24b)によって制限された経路が配置される、請求項1に記載の吸入器(1)。
- マウスピースカバー(2)は、上部ハウジング部材(4a)及び下部ハウジング部材(4b)上を摺動することによって回転運動する、請求項1に記載の吸入器(1)。
- マウスピースカバー(2)は、
−マウスピースカバー(2)が第一位置にあって、マウスピース(14)が完全に覆われて、デバイス(1)が待機モードにある位置と、
−マウスピースカバー(2)が第二位置にあって、デバイス(1)が作動すると、1回分投与量の前記乾燥粉末形態の薬剤に吸入の準備が整う位置、
の2つの位置のみにある、請求項1〜8のいずれか1項に記載の吸入器(1)。 - 前記マウスピースカバーが容易に回転するように、前記マウスピースカバーの一方端に湾曲部分(2a)がある、請求項1に記載の吸入器(1)。
- 前記歯車機構の全構成要素は、直接又は間接的に相互に係合する、請求項1に記載の吸入器(1)。
- 前記歯車機構は、
−マウスピースカバー(2)の一定角度の運動を割り出しラチェットホイール(3)に伝達することによって、デバイス(1)を作動させる駆動歯車(12)と、
−割り出しラチェットホイール(3)と同期し、ブリスター包装体(15)の割り出しを可能にする割り出しホイール(8)と、
−割り出しホイール(8)が回転すると、機構ホイール(5)を介して前記巻取りホイール(13)を動作させる巻取りホイール歯車(6)と、
−割り出しホイール(8)の動作をカウンタホイール(9)に伝達するピニオン歯車(11)及びベース歯車(7)と、
−前記デバイス(1)内に残っている未使用のブリスターポケット(15a)の数を表示する前記カウンタホイール(9)と
で構成される、請求項1又は11に記載の吸入器(1)。 - 上部ハウジング部材(4b)上に空気の流れを提供する少なくとも1つの空気入口(22)がある、請求項1に記載の吸入器(1)。
- 外部空気が前記デバイスに入る空気入口(22)が、前記空気流を妨げないために、前記患者がデバイス(1)を保持する場所に近接しないように設計される、請求項13に記載の吸入器(1)。
- それぞれが乾燥粉末形態の薬剤を含み、等間隔に離間された複数のブリスターポケット(15a)で構成されたブリスター包装体(15)をさらに備える、請求項1〜14のいずれか1項に記載の吸入器(1)。
- 含まれるブリスター包装体(15)は、ブリスターストリップであることが好ましい、請求項1に記載の吸入器(1)。
- 含まれるブリスター包装体(15)は、剥離可能であることが好ましい、請求項1〜16に記載の吸入器(1)。
- 前記ブリスター包装体(15)を構成する蓋シート(15b)及びベースシート(15c)は、複数の層を備えることが好ましい、請求項17に記載の吸入器(1)。
- 前記ブリスター包装体の蓋シート(15b)及びベースシート(15b)を構成する前記層は、様々なポリマー物質で作られることが好ましいポリマー層、アルミニウム箔及びフルオロポリマーフィルムを含む群から選択される、請求項18に記載の吸入器(1)。
- 前記ブリスター包装体の蓋シート(15b)及びベースシート(15b)を構成する前記層の少なくとも1つは、好ましくはシリカゲル、ゼオライト、アルミナ、ボーキサイト、無水硫酸カルシウム、活性炭、及び吸水性を有する粘度、を含む乾燥剤の少なくとも1つを含む、請求項19に記載の吸入器(1)。
- 前記ブリスター包装体の前記蓋シート又は前記ベースシートに含まれる前記アルミニウム箔の厚さは、好ましくは5μm〜80μmの範囲、さらに好ましくは15μm〜65μmの範囲である、請求項21に記載の吸入器(1)。
- 前記ブリスター包装体の蓋シート(15b)又はベースシート(15c)に含まれる前記ポリマー層の厚さは、好ましくは5μm〜100μmの範囲、さらに好ましくは15μm〜60μmの範囲である、請求項19に記載の吸入器(1)。
- 前記乾燥粉末形態の薬剤は、クロモリン、抗感染薬、抗ヒスタミン薬、ステロイド、抗炎症薬、気管支拡張薬、ロイコトリエン阻害薬、PED IV阻害薬、鎮咳薬、利尿薬、抗コリン作用薬、ホルモン、キサンチン及びその薬学的に許容可能な組合せを含む群から選択される少なくとも1つの有効作用物質を含む、請求項1〜22のいずれか1項に記載の前記乾燥粉末形態の薬剤の送達に適した吸入器(1)。
- 前記乾燥粉末形態の薬剤は、単独療法又は併用療法に使用される、請求項1〜23のいずれか1項に記載の前記乾燥粉末形態の薬剤の送達に適した吸入器(1)。
- 前記薬剤は、それに含まれる1つ又は複数の前記有効作用物質とともに少なくとも1つの賦形剤を含む、請求項1〜24のいずれか1項に記載の前記乾燥粉末形態の薬剤の送達に適した吸入器(1)。
- 前記乾燥粉末薬剤に含まれる前記賦形剤は、単糖(ブドウ糖、アラビノースなど)、二糖(ラクトース、蔗糖、麦芽糖など)、オリゴ糖類及び多糖類(デキストランなど)、多価アルコール(ソルビット、マンニット、キシリトール)、塩(塩化ナトリウム、炭酸カルシウムなど)、又はその組合せを含む群から選択可能である、請求項25に記載の前記乾燥粉末形態の薬剤の送達に適した吸入器(1)。
- 前記乾燥粉末薬剤に含まれる前記賦形剤はラクトースであることが好ましい、請求項25又は26に記載の前記乾燥粉末形態の薬剤の送達に適した吸入器(1)。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2010/02877A TR201002877A2 (tr) | 2010-04-13 | 2010-04-13 | Blister ambalaj içeren inhalasyon cihazı |
TR2010/02877 | 2010-04-13 | ||
TR2010/03091 | 2010-04-20 | ||
TR201003091 | 2010-04-20 | ||
TR201004312 | 2010-05-28 | ||
TR2010/04312 | 2010-05-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013504868A Division JP5931848B2 (ja) | 2010-04-13 | 2011-04-13 | 乾燥粉末吸入器のマウスピースボタン |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016135366A true JP2016135366A (ja) | 2016-07-28 |
JP6290969B2 JP6290969B2 (ja) | 2018-03-07 |
Family
ID=44279689
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013504868A Active JP5931848B2 (ja) | 2010-04-13 | 2011-04-13 | 乾燥粉末吸入器のマウスピースボタン |
JP2016089266A Active JP6290969B2 (ja) | 2010-04-13 | 2016-04-27 | 乾燥粉末吸入器のマウスピースボタン |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013504868A Active JP5931848B2 (ja) | 2010-04-13 | 2011-04-13 | 乾燥粉末吸入器のマウスピースボタン |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2566549B1 (ja) |
JP (2) | JP5931848B2 (ja) |
EA (1) | EA027141B1 (ja) |
IN (1) | IN2012DN04993A (ja) |
WO (1) | WO2011129795A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021530469A (ja) * | 2018-06-29 | 2021-11-11 | シーエスピー テクノロジーズ,インコーポレイティド | 低臭気または無臭気吸入乾燥剤ポリマー |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9345848B2 (en) | 2009-10-20 | 2016-05-24 | Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. | Dry powder inhaler |
USD733287S1 (en) | 2011-04-13 | 2015-06-30 | Mahmut Bilgic | Dry powder inhaler |
EP3042681A4 (en) * | 2013-09-02 | 2017-05-17 | Daiwa Can Company | Inhaler |
JP5842020B2 (ja) * | 2014-02-28 | 2016-01-13 | 大和製罐株式会社 | 吸入器 |
JP5842019B2 (ja) * | 2014-02-28 | 2016-01-13 | 大和製罐株式会社 | 吸入器 |
USD744087S1 (en) | 2013-10-01 | 2015-11-24 | Mahmut Bilgic | Dry powder inhaler |
CA2958894A1 (en) | 2014-08-28 | 2016-03-03 | Microdose Therapeutx, Inc. | Compliance monitoring module for a breath-actuated inhaler |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537377A (ja) * | 2001-08-09 | 2004-12-16 | グラクソ グループ リミテッド | 製薬組成物を有する吸入装置 |
JP2009518093A (ja) * | 2005-12-12 | 2009-05-07 | グラクソ グループ リミテッド | 薬剤ディスペンサ用のマニホルド |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0125135D0 (en) * | 2001-10-19 | 2001-12-12 | Glaxo Group Ltd | Medicament dispenser |
GB0209526D0 (en) * | 2002-04-26 | 2002-06-05 | Glaxo Group Ltd | Medicament dispenser |
GB0317374D0 (en) * | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
WO2005079727A2 (en) * | 2004-02-16 | 2005-09-01 | Glaxo Group Limited | Counter for use with a medicament dispenser |
GB0509952D0 (en) * | 2005-05-16 | 2005-06-22 | Glaxo Group Ltd | Fault indicator |
DE102006043637A1 (de) * | 2006-05-18 | 2007-11-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Zerstäuber |
-
2011
- 2011-04-13 EP EP11720619.3A patent/EP2566549B1/en active Active
- 2011-04-13 EA EA201201395A patent/EA027141B1/ru unknown
- 2011-04-13 JP JP2013504868A patent/JP5931848B2/ja active Active
- 2011-04-13 WO PCT/TR2011/000095 patent/WO2011129795A1/en active Application Filing
-
2012
- 2012-06-06 IN IN4993DEN2012 patent/IN2012DN04993A/en unknown
-
2016
- 2016-04-27 JP JP2016089266A patent/JP6290969B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537377A (ja) * | 2001-08-09 | 2004-12-16 | グラクソ グループ リミテッド | 製薬組成物を有する吸入装置 |
JP2009518093A (ja) * | 2005-12-12 | 2009-05-07 | グラクソ グループ リミテッド | 薬剤ディスペンサ用のマニホルド |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021530469A (ja) * | 2018-06-29 | 2021-11-11 | シーエスピー テクノロジーズ,インコーポレイティド | 低臭気または無臭気吸入乾燥剤ポリマー |
JP7522719B2 (ja) | 2018-06-29 | 2024-07-25 | シーエスピー テクノロジーズ,インコーポレイティド | 低臭気または無臭気吸入乾燥剤ポリマー |
Also Published As
Publication number | Publication date |
---|---|
EP2566549A1 (en) | 2013-03-13 |
EA027141B1 (ru) | 2017-06-30 |
WO2011129795A1 (en) | 2011-10-20 |
IN2012DN04993A (ja) | 2015-10-02 |
JP2013523382A (ja) | 2013-06-17 |
EP2566549B1 (en) | 2017-03-22 |
JP6290969B2 (ja) | 2018-03-07 |
JP5931848B2 (ja) | 2016-06-08 |
EA201201395A1 (ru) | 2014-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6290969B2 (ja) | 乾燥粉末吸入器のマウスピースボタン | |
US9795751B2 (en) | Dry powder inhaler | |
JP5860869B2 (ja) | 吸入デバイス | |
JP2013523375A (ja) | 乾燥粉末吸入器のマウスピースボタン | |
JP5855642B2 (ja) | 乾燥粉末吸入器のマウスピースボタン | |
JP5857034B2 (ja) | ブリスター包装体を有する吸入器 | |
WO2011129788A1 (en) | User-friendly dry powder inhaler | |
JP2013523378A (ja) | 乱流を生成する吸入器 | |
JP5873477B2 (ja) | 乾燥粉末形態の薬剤の送達に使用する吸入器 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160509 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160509 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170330 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170929 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180202 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6290969 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |